Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia [PDF]
Haematologica, 2017 Our aim was to improve outcome prediction after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia by combining cytogenetic and molecular data at diagnosis with minimal residual disease assessment by multicolor flow-cytometry at
Betül Oran +17 more
doaj +3 more sources
Strategies for minimal residual disease detection: current perspectives [PDF]
Blood and Lymphatic Cancer: Targets and Therapy, 2019 Giacomo Andreani, Daniela Cilloni Department of Clinical and Biological Sciences, University of Turin, Turin, Italy Abstract: Currently, the post-remission treatment in acute leukemia is based on the genetic profile of leukemic cells at diagnosis (ie ...
Andreani G, Cilloni D
doaj +1 more source
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia [PDF]
Haematologica, 2019 A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods.
Esther Onecha +21 more
doaj +3 more sources
Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemia [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2015 Introduction: Minimal residual disease is an important independent prognostic factor that can identify poor responders among patients with acute lymphoblastic leukemia.
Francisco Danilo Ferreira Paula +7 more
doaj +2 more sources
Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2013 OBJECTIVE To detect markers for minimal residual disease monitoring based on conventional polymerase chain reaction for immunoglobulin, T-cell receptor rearrangements and the Sil-Tal1 deletion in patients with acute lymphocytic leukemia. METHODS Fifty-
Juliana Godoy Assumpcao +8 more
doaj +2 more sources
The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy [PDF]
Haematologica, 2014 A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any ...
Rodrigo Santacruz +17 more
doaj +3 more sources
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? [PDF]
The Journal of Liquid BiopsyDespite a significant evolution in treatment strategies for early breast cancer (EBC) patients, up to 30% of them experience recurrence due to occult micrometastasis.
Mara S. Serafini +5 more
doaj +3 more sources
Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia [PDF]
Clinical Medicine Insights: Oncology, 2015 Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related death in children and adolescents. Minimal residual disease (MRD) is a strong, independent prognostic factor.
Jitsuda Sitthi-amorn +7 more
doaj +2 more sources
Assessment of minimal residual disease in standard-risk AML [PDF]
, 2016 Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of remission.
Griffiths, M +21 more
core +9 more sources
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse [PDF]
, 2012 This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion.
Meyer, Claus +23 more
core +1 more source